Nerivio® | REN Wearable for Migraine by Theranica

It’s time to rethink how migraine is treated. Let’s make a difference by advocating for innovative, non-pharmacological migraine treatments that improve patient outcomes, reduce disease burden, and modernize care. The Nerivio® REN wearable is the only FDA-cleared migraine treatment for adults and children ages 8 and up, offering both preventive and acute therapy in a single, non-drug, needle-free option. Why Does This Matter? Migraine isn’t just episodic event—it’s a progressive neurological disease. Yet, despite being the second leading cause for disability worldwide, it remains widely underdiagnosed and undertreated [1]. Delaying preventive treatment and lacking sub-optimal acute treatment can lead to worsening outcomes [2]. Left unmanaged, migraine can chronify, increasing disease burden, reducing quality of life, and driving up healthcare costs. Incorporating wearable, neuromodulation-based therapy into early treatment plans may help: ✔ Reduce the use of acute migraine medications [3] ✔ Reduce the risk for medication overuse headache (MOH) [3] ✔ Empower patients to regain control over their migraine management [4,5] With the Nerivio® REN wearable, clinicians can offer a safe and effective treatment that is [6]: ✔ Drug-free ✔ Non-invasive ✔ Non-addictive ✔ Non-sedative ✔ Without systemic side effects or drug interactions Nerivio is an especially valuable option for children, veterans, and patients seeking drug-free migraine care. The safety and efficacy of Nerivio have been evaluated in 16 clinical trials involving over 15,000 patients. For full clinical data and important safety information, visit www.nerivio.com Nerivio is developed by @Theranica, a leader in digital pain therapeutics. References: [1] Perry et al. 2022 [2] Gottschalk et al. 2022 [3] Marmura et. al. 2020 [4] Bentivegna et al. 2023 [5] Solomon 2020 [6] https://www.nerivio.com/clinical-trials